Search results
Results from the WOW.Com Content Network
The MOMS Trial was a clinical trial that studied treatment of a birth defect called myelomeningocele, which is the most severe form of spina bifida. The study looked at prenatal (before birth) and postnatal (after birth) surgery to repair this defect. The first major phase concluded that prenatal surgery had strong, long-term benefits and some ...
A lumbar myelomeningocele. Myelomeningocele (MMC), also known as meningomyelocele, is the type of spina bifida that often results in the most severe complications and affects the meninges and nerves. [30] In individuals with myelomeningocele, the unfused portion of the spinal column allows the spinal cord to protrude through an opening.
If the pregnancy is low risk to develop a neural tube defect then the recommendation for that individual is 0.4 mg daily until 4–6 weeks postpartum or however long breastfeeding lasts. [62] All dose recommendations and risk assessment should be done with the advice of a qualified health care provider. [61]
Among the first dozen reported attempts at this repair in the 1990s, only two children survived long-term. [13] [quantify] Dr. Oluyinka Olutoye, alongside Darrell Cass, from the Texas Children's Fetal Centre, removed a 23-week-old fetus from her mother's womb in order to perform surgery upon a spinal tumor she had. The girl was placed back in ...
Myelomalacia is a pathological term referring to the softening of the spinal cord. [1] Possible causes of myelomalacia include cervical myelopathy, hemorrhagic infarction, or acute injury, such as that caused by intervertebral disc extrusion.
In neurology, a lipomyelomeningocele is a type of closed neural tube defect that affects around 3 to 6 babies out of 100,000 births. [1] [2] It is an example of a spinal lipoma, which is a collection of adipose tissue, or fat, that is located at or around the spinal cord.
The limit of viability is the gestational age at which a prematurely born fetus/infant has a 50% chance of long-term survival outside its mother's womb. With the support of neonatal intensive care units, the limit of viability in the developed world has declined since the 1960s. [33] [34]
Survival rate is a part of survival analysis.It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy.